primaquine has been researched along with oz 439 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fidock, DA; Flannery, EL; Winzeler, EA | 1 |
| Hoda, N; Madhav, H | 1 |
| Blagborough, AM; Brock, PM; Churcher, TS; Delves, MJ; Gething, PW; Ghani, AC; Leroy, D; Sala, KA; Sinden, RE; Upton, LM | 1 |
| Adams, M; Bousema, T; Chalon, S; Collins, KA; Elliott, S; McCarthy, JS; Mitchell, H; Möhrle, JJ; Rampton, M; Reuling, IJ; Sauerwein, R; Wang, CY | 1 |
| Akakpo, S; Chalon, S; Chughlay, MF; Csermak-Renner, K; Djeriou, E; Gaur, AH; Leboulleux, D; McCarthy, J; Odedra, A; Shanks, GD; Winnips, C | 1 |
| Koonyosying, P; Srichairatanakool, S; Sthitmatee, N; Tiwananthagorn, S | 1 |
2 review(s) available for primaquine and oz 439
| Article | Year |
|---|---|
Using genetic methods to define the targets of compounds with antimalarial activity.
Topics: Animals; Anopheles; Antimalarials; Drug Resistance; Genetic Association Studies; Genome, Protozoan; Humans; Malaria, Falciparum; Molecular Targeted Therapy; Plasmodium falciparum | 2013 |
An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.
Topics: Animals; Antimalarials; Drug Development; Drug Resistance; Humans; Malaria; Molecular Targeted Therapy; Plasmodium; Protozoan Proteins; Small Molecule Libraries | 2021 |
1 trial(s) available for primaquine and oz 439
| Article | Year |
|---|---|
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Models, Biological; Peroxides; Plasmodium falciparum; Primaquine; Quinolines | 2018 |
3 other study(ies) available for primaquine and oz 439
| Article | Year |
|---|---|
Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.
Topics: Adamantane; Animals; Anopheles; Antimalarials; Artemether; Artemisinins; Ethanolamines; Female; Fluorenes; Indoles; Insect Vectors; Lumefantrine; Malaria; Mice; Peroxides; Plasmodium berghei; Primaquine; Spiro Compounds | 2015 |
Liver Enzyme Elevations in
Topics: Acrylamides; Adamantane; Adult; Alanine Transaminase; Aminopyridines; Aminoquinolines; Antimalarials; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Erythrocyte Transfusion; Erythrocytes; Female; Ferrous Compounds; Healthy Volunteers; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Isoquinolines; Malaria, Falciparum; Male; Metallocenes; Parasitemia; Peroxides; Piperazines; Plasmodium falciparum; Primaquine; Pyrimidines; Quinolines; Spiro Compounds; Sulfones; Triazoles; Young Adult | 2020 |
Inhibitory effects on bovine babesial infection by iron chelator, 1-(N-acetyl-6-aminohexyl)- 3-hydroxy-2-methylpyridin-4-one (CM1), and antimalarial drugs.
Topics: Animals; Antimalarials; Babesia; Babesiosis; Cattle; Cattle Diseases; Chloroquine; Humans; Inhibitory Concentration 50; Iron Chelating Agents; Mammals; Primaquine; Pyrimethamine | 2023 |